Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.
Hoffmann-La Roche
High-risk hepatocellular carcinoma (HCC)
1 trial -
Tecentriq 840 mg concentrate for solution for infusion
Novo Nordisk A/S
Metastatic pancreatic ductal adenocarcinoma (mPDAC)
1 trial -
Tecentriq concentrate for solution for infusion placebo 0mg, Tecentriq 840 mg concentrate for solution for infusion
Hoffmann-La Roche
High-risk muscle-invasive bladder cancer
1 trial -
Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)
Eastern Hepatobiliary Surgery Hospital
Gastric Cancer
1 trial -
Telavancin
CUMBERLAND PHARMACEUTICALS INC
Staphylococcal Skin Infection
2 trials -
Topotecan HEXAL 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Anastrozol STADA® 1 mg Filmtabletten, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, VS-6766, LETRO-cell® 2,5 mg Filmtabletten, VS-6063, Letrozol - 1 A Pharma® 2,5 mg Filmtabletten, ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for inf
Vera Therapeutics
Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
1 trial -
UVEDOSE 100 000 UI, solution buvable en ampoule
Novo Nordisk A/S
Thyroidectomy is a common operation. Transient postoperative hypocalcemia is the main complication, resulting in clinical discomfort for patients, longer hospital stays and increased perioperative cost. Cholecalciferol is used to supplement vitamin D deficiency. We suppose that systematic pre-operative supplementation with cholecalciferol would allow a faster and more appropriate response to post-operative hypocalcemia
1 trial -
VINCRISTINE SULFATE, RITUXIMAB, RITUXIMAB, APIXABAN, Golcadomide, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE MONOHYDRATE, Golcadomide, Golcadomide 0.2 mg capsule, Golcadomide 0.3 mg capsule, Golcadomide 0.4 mg capsule, Golcadomide, Neulasta 6 mg solution for injection, PREDNISOLONE , VINCRISTINE SULFATE
Celgene Europe Limited
High-risk Large B-cell Lymphoma
1 trial -
Valbenazine
NEUROCRINE BIOSCIENCES INC
Tardive Dyskinesia
2 trials -
Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed), Pneumococcal Conjugate Vaccine (PCV)
Sanofi-aventis Healthcare Pty Ltd
Pneumococcal Immunization
1 trial -
Vehicle to Mecloderm Ointment, LOTRICOMB® Salbe, 0,64 mg/g + 10 mg/g, Salbe, Mecloderm Ointment
Alphapharm Pty Ltd
moderate to severely inflamed candidiasis of the skin
1 trial -
Venclexta, Venclyxto, Levact 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Venclexta, Venclyxto, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Venclexta, Venclyxto, Fludarabin Ebewe 25 mg/ml injektio-/infuusiokonsentraatti, liuosta varten, Fludarabin Sandoz 25 mg/ml injekčný alebo infúzny koncentrát, MabThera 500 mg concentrate for solution for infusion, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, Bendamustin cell pharm® 2,5
Hoffmann-La Roche
Chronic Lymphocytic Leukemia (CLL)
1 trial -
Venetoclax, Venetoclax, Venetoclax, Vidaza 25 mg/ml powder for suspension for injection, Placebo Venetoclax/ABT-199/Film-coated tablet Oral Use
AbbVie Deutschland GmbH & Co. KG
Higher-Risk Myelodysplastic Syndrome
1 trial -
Zilebesiran
Alnylam Netherlands B.V.
High Risk Cardiovascular Disease
1 trial -
Ziltivekimab
Novo Nordisk A/S
Heart Failure
1 trial -
bimekizumab, Skyrizi 150 mg solution for injection in pre-filled syringe, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized).
Lacuna Pharma Pty Ltd
Psoriatic arthritis
1 trial -
biphasic insulin aspart
Novo Nordisk A/S
Diabetes
1 trial -
desiccated thyroid extract (DTE)+levothyroxine (L-T4)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Intermediate-to-High Risk Differentiated Thyroid Cancer
1 trial -
eptacog alfa (activated)
Novo Nordisk A/S
Acquired Bleeding Disorder
1 trial -
insulin degludec
Novo Nordisk A/S
Diabetes
2 trials -
lipegfilgrastim
Teva Pharma GmbH
Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia
1 trial -
liraglutide
Novo Nordisk A/S
Metabolism and Nutrition Disorder
1 trial -
liraglutide
Novo Nordisk A/S
Diabetes
2 trials -
mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Merck Sharp and Dohme
The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources